In prostate cancer, most recommendations adhere to the age range of 50–55 to consider starting PSA screening if life expectancy exceeds 10 years, and 40–45 for men with increased familial and genetic predisposition, although high-quality evidence for the benefit outweighing the possible risks, even in the latter subgroup, is lacking. This evidence concerns the gene KLK3 and Familial prostate cancer.